14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ELVN vs ACAD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Acadia Pharmaceuticals Inc. (ACAD) is the stronger overall head-to-head candidate over Enliven Therapeutics, Inc. (ELVN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ELVN carries a Unified Composite Score of 35.9/100 (SELL) at $47.54 (N/M Forward P/E, 0.0% operating margin), whereas ACAD carries 46.7/100 (HOLD) at $19.07 (17.8x Forward P/E, 10.2% operating margin).
Technical & Structure Timing Caution: ELVN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.3); meanwhile ACAD is in a Breakdown options structure phase (RSI 45.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ELVN vs ACAD. Trailing 12-month operating profitability (ELVN 0.0% vs ACAD 10.2%) and valuation multiples (ELVN N/M vs ACAD 17.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.1B market capitalization and 10.2% operating margin.
OpEx & R&D Reinvestment53.7% of Rev ($646M)
90D Engineering Disclosures0 Published
Investor FAQ ELVN vs ACAD Key Questions & Quantitative Answers
As of Nov 16, 2026, Acadia Pharmaceuticals Inc. (ACAD) is the stronger overall head-to-head candidate over Enliven Therapeutics, Inc. (ELVN) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ELVN carries a Unified Composite Score of 35.9/100 (SELL) at $47.54 (N/M Forward P/E, 0.0% operating margin), whereas ACAD carries 46.7/100 (HOLD) at $19.07 (17.8x Forward P/E, 10.2% operating margin). Technical & Structure Timing Caution: ELVN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 54.3); meanwhile ACAD is in a Breakdown options structure phase (RSI 45.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ACAD leads the Growth & Scale pillar: ELVN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ACAD at +22.8% YoY revenue growth and -26.2% YoY earnings growth on $1.20B TTM revenue (63.9% gross margin, 10.2% operating margin). On trailing 12-month operating scale, ELVN generates N/A in USD-normalized revenue versus $1.20B for ACAD. In operating R&D and SG&A reinvestment, ELVN deploys N/A (0 90-day corporate R&D disclosures) versus 53.7% of Rev ($646M) (0 disclosures) for ACAD.
ACAD screens cheaper on headline valuation multiples. ELVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ACAD trades at 17.8x Forward P/E, 8.6x Trailing P/E, N/M PEG, and 2.4x EV/Revenue (15.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ELVN (-16.8% ROE) versus ACAD (31.4% ROE) capital efficiency.
In options market volatility and institutional positioning, ELVN carries 46.9% implied volatility (5th %ile, Compressed (<25th %ile)), a 1.67x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.96β · 60% Vol realized risk). By comparison, ACAD carries 42.6% implied volatility (4th %ile, Compressed (<25th %ile)), a 0.33x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.11β · 93% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.